Last reviewed · How we verify
HIV-1 infection in combination with other antiretroviral agents — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Riv | riv | Pfizer | Protease Inhibitors | HIV-1 protease |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in HIV-1 infection in combination with other antiretroviral agents
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in HIV-1 infection in combination with other antiretroviral agents:
- HIV-1 infection in combination with other antiretroviral agents treatment updates — RSS
- HIV-1 infection in combination with other antiretroviral agents treatment updates — Atom
- HIV-1 infection in combination with other antiretroviral agents treatment updates — JSON
Cite this brief
Drug Landscape (2026). HIV-1 infection in combination with other antiretroviral agents — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents. Accessed 2026-06-10.
Related
- HIV-1 infection in combination with other antiretroviral agents full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing